Stock Events

Stock Events

Advicenne 

€2.14
11
+€0+0% Friday 17:35

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26MarExpected
Q4 2023
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.47
-0.45
-0.42
-0.4
Expected EPS
N/A
Actual EPS
N/A

Financials

-238.01%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
4.52MRevenue
-10.77MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADVIC.PA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals is a competitor because it develops and markets drugs for treating cystic fibrosis, a focus area that overlaps with Advicenne's work on kidney and metabolic disorders.
Novartis
NVS
Mkt Cap297.35B
Novartis is a global healthcare company that has a broad portfolio, including treatments for chronic kidney disease, making it a competitor.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca operates in various therapeutic areas, including cardiovascular, renal, and metabolism, competing with Advicenne's products.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical focuses on rare genetic diseases, some of which affect metabolic processes similar to Advicenne's target disorders.
AMGEN
AMGN
Mkt Cap189.22B
Amgen has a diverse portfolio that includes treatments for bone and kidney diseases, areas that overlap with Advicenne's interests.
Pfizer
PFE
Mkt Cap153.13B
Pfizer has a broad range of products, including treatments for kidney diseases, competing in the same market as Advicenne.
Sanofi
SNY
Mkt Cap113.88B
Sanofi focuses on a wide array of therapeutic areas, including rare diseases, which puts it in competition with Advicenne.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline has a diverse pharmaceutical portfolio, including areas that compete with Advicenne's focus on kidney and metabolic disorders.

About

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Show more...
CEO
Ms. Caroline Roussel-Maupetit
Employees
32
Country
France
ISIN
FR0013296746
WKN
000A2H8SU

Listings

F
DE
3MM.F
MU
DE
3MM.MU
STU
DE
3MM.STU
Grey Market
US
ADVVF

0 Comments

Share your thoughts

FAQ

What is Advicenne stock price today?▼
The current price of ADVIC.PA is €2.14 EUR — it has increased by +0% in the past 24 hours. Watch Advicenne stock price performance more closely on the chart.
What is Advicenne stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Advicenne stocks are traded under the ticker ADVIC.PA.
What is Advicenne revenue for the last year?▼
Advicenne revenue for the last year amounts to 4.52M EUR.
What is Advicenne net income for the last year?▼
ADVIC.PA net income for the last year is -10.77M EUR.
How many employees does Advicenne have?▼
As of April 13, 2026, the company has 32 employees.
In which sector is Advicenne located?▼
Advicenne operates in the Health & Wellness sector.
When did Advicenne complete a stock split?▼
Advicenne has not had any recent stock splits.
Where is Advicenne headquartered?▼
Advicenne is headquartered in Paris, France.